Explaining the Process of Engagement


This panel focuses on angels in Biotech investment and how angels assess current biotech investment trends and criteria. Topics may include:

  • Types of deals Biotech angels like to do
  • What it’s like to work with an angel investor
  • How biotech and investment landscapes evolving

Angel investors have been one of the first go-to investors as an incredibly important source of capital for fundraising entrepreneurs. Panelists will highlight the perspective of an angel when approaching a deal in the space. Angels will explain their investment preferences and their evaluation criteria, and provide overall advice in how to approach and build relationships with them. The panel will serve as an educational opportunity for scientist entrepreneurs to better understand the trends in angel investment in the bio-pharmaceutical field.


Request a Meeting

Jeff Arnold, Member, Boston Harbor Angels (Moderator)

Mr. Arnold is the president of Arnold Strategies, LLC, a strategic advisor to early and growth stage CEO’s, and an angel investor with Mass Medical Angels and Boston Harbor Angels. As an angel investor, Mr. Arnold, has invested in, among others, SmartCells (sold to Merck), BioAssets development Corp (sold to Cephalon), Syntonix (sold to Biogen Idec), Health Honors (sold to Healthway) and JB Therapeutics (now public as Corbus Pharmaceutical Holdings). Prior to founding Arnold Strategies, Mr. Arnold spent 20 years as the CEO of multiple private and public technology and life science companies. Among these include Cambridge Heart, a cardiology diagnostics company which he founded and took public, CardioFocus, a VC backed catheter ablation company and Accelrys, a public company with software tools for rational drug design, now a division of Dassault Systemes. Mr. Arnold is a guest lecturer at the MIT Sloan School, mentor at the MIT Venture Mentoring Society, on the Grant Review Board of the MIT Deshpande Center and on the Board of Overseers at the Museum of Science. He was formerly Chairman of the Greater Boston Chapter of the American Heart Association. He received a BSEE from MIT in 1972.

Request a Meeting

Yaniv Sneor, Founding Member Mid Atlantic Bio Angels

Yaniv Sneor is a (reformed) physicist, who made the transition into the business world after being bitten by the entrepreneurial bug. Yaniv has been involved in founding, growing, managing and re-engineering companies for the past 25+ years, in multiple industries. He ran companies of different sizes and at different life-stages, led re-structuring activities, purchased and sold multiple companies, and negotiated and integrated joint ventures and strategic relationships.Yaniv is one of the founders of MABA – Mid Atlantic Bio Angels ( a life science angel investor group. He is president of Blue Cactus Consulting (, and CEO of Native State Therapeutics, a recently-formed biotechnology company, in the neurodegenerative space.

Request a Meeting

Ozan Isinak, President, Central Canada Keiretsu Forum

Mr. Isinak is a serial entrepreneur, investor and alternative investment expert with over 25 years of international experience within the angel investment, venture capital and private equity sectors. Ozan worked in Silicon Valley during the first dotcom boom throughout the 1990’s where he helped secure strategic investor and digital business initiatives of fortune 1000 companies in San Francisco, Los Angeles, Seattle, New York, Toronto, Hamburg, Stockholm, London and Istanbul. Ozan later acted as General Partner in various angel investment and private equity practices.

He is currently the President of Keiretsu Forum’s Canada region, the world’s largest angel investment network operating on three continents. The global network specializes in syndication of deals and invested over $73 million USD into 168 early stage companies in 2016 alone.

Mr. Isinak is also the co-founder of Headwayz, an international platform for angel backed companies looking to grow through mergers, acquisitions and joint ventures. The platform currently attracts startup deal flow originating from 25 countries from North America, Asia, Europe and the Middle East.

Ozan received his MBA in Finance from the University of San Francisco – McLaren School of Business in 1998 and holds a double major in Economics & Political Science from the University of Western Ontario (1994). He speaks English, Turkish and French.

Request a Meeting

Prathna Ramesh, Executive Director, Maple Leaf Angels (MLA)

Prathna joined MLA in 2017. As Managing Director, she works collaboratively with MLA’s Board of Directors to set overall strategic and operational objectives for the group. She manages the MLA48 Fund I & II Limited Partnership, an Angel fund making investment decisions in 48 hours. Prior to this, she worked with About Communications, a Telecommunications & Information Technology firm. Prathna brings experience in account management, client operations and project management. She holds a B.Com degree from the Rotman Commerce Program at the University of Toronto.

Request a Meeting

Norm Gitis, Founder, Managing Partner, Lymo Ventures

Norm has a Ph.D. in engineering, was a visiting professor at MIT, advisory engineer at IBM, engineering manager at Maxtor. He founded and led a high-tech company making scientific instrumentation and became a Silicon Valley entrepreneur. After selling the company with multiple offers, he founded a multi-family office, which actively invests in start-ups, mostly in California and New England. Currently, Lymo Ventures has an active portfolio of 17 companies, about three quarters of them are in med-tech.

Norm chairs Boards of directors of two med-tech companies, serves on a Board of a medical diagnostics company, is an active mentor of numerous start-up companies, managing partner of the multi-family office, and a member of screening committees of prominent angel associations in Silicon Valley, including Band of Angels and Life Science Angels.